TITLE

Review: Anticholinergics, but not β2-agonists, reduce exacerbations requiring hospitalization and respiratory deaths in COPD

AUTHOR(S)
Shafazand, Shirin
PUB. DATE
January 2007
SOURCE
ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the use of anticholinergics for treating patients suffering from pulmonary diseases. It reduces exacerbations requiring hospitalization and respiratory deaths from chronic obstructive pulmonary disease. A comparison was also made between the anticholinergics therapy and the β2-agonists therapy which revealed that the former was better in curing pulmonary diseases.
ACCESSION #
23847349

 

Related Articles

  • Safety of Inhaled Anticholinergics for COPD Scrutinized. Elliott, William T. // Critical Care Alert;Nov2008 Pharmacology Watch, p1 

    The article focuses on the safety of inhaled anticholinergics for the treatment of chronic obstructive pulmonary disease (COPD).

  • Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies.  // Thorax;May2008, Vol. 63 Issue 5, p415 

    Background: A study was undertaken to determine whether a short course of antibiotic treatment ((5 days) is as effective as the conventional longer treatment in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD). Methods: MEDLINE, EMBASE and the Cochrane...

  • Integrated care: delivering better outcomes for patients with respiratory disease. Partridge, Martyn R. // British Journal of Healthcare Management;2015, Vol. 21 Issue 1, p7 

    No abstract available.

  • Tiotropium and chronic obstructive pulmonary disease. McIvor, R. Andrew // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/13/2010, Vol. 340 Issue 7746, p546 

    The author argues that the inhaled, long acting anticholinergic drug tiotropium is a safe and effective foundation treatment for patients with chronic obstructive pulmonary disease (COPD). The benefits of the drug based on the results of several clinical trials are cited, including improvements...

  • Inhaled anticholinergics for COPD. Tanzi, Maria G. // Pharmacy Today;Dec2008, Vol. 14 Issue 12, p23 

    The article presents a study concerning the effectiveness of the inhaled anticholinergics for chronic obstructive pulmonary disease (COPD) treatment. Research shows that anticholinergics such as ipratropium and tiotropium were associated with increased risk for cardiovascular death in patients...

  • Optimal treatment for COPD. Lewis, Laurie // Patient Care;5/30/2000, Vol. 34 Issue 10, p60 

    Explains that chronic obstructive pulmonary disease (COPD) is curable and that prevention is the only way to reduce the human and financial costs of the disease. Availability of pharmacologic and nonpharmacologic treatments; Use of spirometry in diagnosing and monitoring COPD; Pulmonary...

  • Tiotropium for uncontrolled asthma.  // Neurology Alert;Dec2010 Supplement, p1 

    The article focuses on a study which investigated the therapeutic use of tiotropium, a long-acting anticholinergic inhaler, for patients with chronic obstructive pulmonary disease (COPD).

  • Tiotropium for Uncontrolled Asthma.  // Internal Medicine Alert;12/15/2010 Clinical Briefs, p1 

    The article reports on the findings of a study that suggest that tiotropium, a long-acting anticholinergic inhaler, has been approved for the treatment of chronic obstructive pulmonary disease.

  • New treatment for COPD launched.  // Pulse;9/9/2002, Vol. 62 Issue 34, p4 

    Announces the launch of Spiriva, an anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease by Boehringer Ingelheim and Pfizer in Great Britain.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics